Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

PubMed  Google Scholar 

Corzo C, Barrientos Santillan N, Westin SN, Ramirez PT. Updates on conservative management of endometrial cancer. J Minim Invasive Gynecol. 2018;25(2):308–13.

PubMed  Google Scholar 

Puppo A, Fraternali Orcioni G, Clignon V, Musizzano Y, Zavattero CA, Vocino Trucco G, et al. Where morphological and molecular classifications meet: the role of p53 immunohistochemistry in the prognosis of low-risk endometrial carcinoma (GLAMOUR Study). Cancers (Basel). 2024;16(6):1088.

PubMed  CAS  Google Scholar 

Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, et al. Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations, part II. Gynecol Oncol. 2021;160(3):827–34.

PubMed  Google Scholar 

Ran X, Hu T, Li Z. Molecular classification in patients with endometrial cancer after fertility-preserving treatment: application of ProMisE classifier and combination of prognostic evidence. Front Oncol. 2022;19:12.

Google Scholar 

Zhang X, Chen D, Zhao X, Wang C, He Y, Chen Y, et al. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia. Pathol Res Pract. 2023;241:154278.

PubMed  CAS  Google Scholar 

Chung YS, Woo HY, Lee JY, Park E, Nam EJ, Kim S, et al. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer. Am J Obstet Gynecol. 2021;224(4):370.e1-370.e13.

PubMed  CAS  Google Scholar 

Puechl AM, Spinosa D, Berchuck A, Secord AA, Drury KE, Broadwater G, et al. Molecular classification to prognosticate response in medically managed endometrial cancers and endometrial intraepithelial neoplasia. Cancers (Basel). 2021;13(11):2847.

PubMed  CAS  Google Scholar 

Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023;162(2):383–94.

PubMed  Google Scholar 

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, et al. Confirmation of promise: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123(5):802–13.

PubMed  CAS  Google Scholar 

Arciuolo D, Travaglino A, Raffone A, Raimondo D, Santoro A, Russo D, et al. TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives. Int J Mol Sci. 2022;23(19):11684.

PubMed  PubMed Central  Google Scholar 

Britton H, Huang L, Lum A, Leung S, Shum K, Kale M, et al. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecol Oncol. 2019;153(3):487–95.

PubMed  Google Scholar 

Rodolakis A, Scambia G, Planchamp F, Acien M, Di Spiezio Sardo A, Farrugia M, et al. ESGO/ESHRE/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Hum Reprod Open. 2023;2023(1):hoac057.

PubMed  PubMed Central  Google Scholar 

Gallo A, Catena U, Saccone G, Di Spiezio Sardo A. Conservative surgery in endometrial cancer. J Clin Med. 2021;11(1):183.

PubMed  PubMed Central  Google Scholar 

Kim MK, Seong SJ, Kim JW, Jeon S, Choi HS, Lee IH, et al. Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: a Korean gynecologic-oncology group study. Int J Gynecol Cancer. 2016;26(4):711–5.

PubMed  Google Scholar 

Pino I, Iacobone AD, Vidal Urbinati AM, Di Giminiani M, Radice D, Guerrieri ME, et al. Fertility-sparing treatment for endometrial cancer: oncological and obstetric outcomes in combined therapies with levonorgestrel intrauterine device. Cancers (Basel). 2022;14(9):2170.

PubMed  CAS  Google Scholar 

Mutlu L, Manavella DD, Gullo G, McNamara B, Santin AD, Patrizio P. Endometrial cancer in reproductive age: fertility-sparing approach and reproductive outcomes. Cancers (Basel). 2022;14(21):5187.

PubMed  CAS  Google Scholar 

Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180–8.

PubMed  CAS  Google Scholar 

Lim P, Aquino-Parsons CF, Wong F, Dupuis B, Phillips D, Zhou C, et al. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators. Gynecol Oncol. 1999;73(2):191–5.

PubMed  CAS  Google Scholar 

Vermij L, Léon-Castillo A, Singh N, Powell ME, Edmondson RJ, Genestie C, et al. P53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial. Mod Pathol. 2022;35(10):1475–83.

PubMed  PubMed Central  CAS  Google Scholar 

Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, et al. TP53 sequencing and p53 immunohistochemistry predict outcomes when bevacizumab is added to frontline chemotherapy in endometrial cancer: an NRG oncology/gynecologic oncology group study. J Clin Oncol. 2022;40(28):3289–300.

PubMed  PubMed Central  CAS  Google Scholar 

Agusti N, Kanbergs A, Nitecki R. Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer. Gynecol Oncol. 2024;185:121–7.

PubMed  PubMed Central  CAS  Google Scholar 

Peng H, Jiang J, Li L, Hao Z, Lian H, Du H, et al. Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment. Gynecol Oncol. 2024;186:154–60.

PubMed  CAS  Google Scholar 

Momeni-Boroujeni A, Dahoud W, Vanderbilt CM, Chiang S, Murali R, Rios-Doria EV, et al. Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas. Clin Cancer Res. 2021;27(9):2613–23.

PubMed  PubMed Central  CAS  Google Scholar 

Nierengarten MB. FDA approves capivasertib with fulvestrant for breast cancer. Cancer. 2024;130(6):835–6.

PubMed  Google Scholar 

Fabi F, Adam P, Parent S, Tardif L, Cadrin M, Asselin E. Pharmacologic inhibition of Akt in combination with chemotherapeutic agents effectively induces apoptosis in ovarian and endometrial cancer cell lines. Mol Oncol. 2021;15(8):2106–19.

PubMed  PubMed Central  CAS  Google Scholar 

Kyo S, Nakayama K. Endometrial cancer as a metabolic disease with dysregulated PI3K signaling: shedding light on novel therapeutic strategies. Int J Mol Sci. 2020;21(17):6073.

PubMed  PubMed Central  CAS  Google Scholar